Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219238 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
A Phase 2 study, sponsored by GE Healthcare.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT07219238: Recruiting Phase 2 study, sponsored by GE Healthcare.
NCT07219238 is a Phase 2 study that is actively recruiting participants, run by GE Healthcare. The registered enrollment target is 175 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219238, a Phase 2 study, is actively recruiting participants, sponsored by GE Healthcare.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET/CT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study. The study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET/CT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET/CT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.
Primary Outcome
The co-primary efficacy endpoint is based on region level sensitivity and specificity of GEH300079 (68Ga) PET/CT imaging for the detection of PC in participants with colorectal, gastric or ovarian primary cancer. GEH300079 (68Ga) PET/CT images collected during the Phase 2 part will be reviewed by 5 independent readers. Images collected during the Phase 3 part will be reviewed by 3 readers. The superiority of per region sensitivity (respectively specificity) to a pre-specified threshold of 75% (r
Interventions
- DRUG GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2026-10 |
| Est. Completion | 2029-08 |
| Phase | Phase 2 |
What NCT07219238 shows while recruiting
NCT07219238 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 1 intervention - of which GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) is the first listed.
NCT07219238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07219238 about?
NCT07219238 is a clinical study titled "Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)". This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcino...
What is the current status of trial NCT07219238?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2026-10. Estimated completion is 2029-08.
What interventions are being tested in trial NCT07219238?
The interventions under investigation include: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) (DRUG).
Who is sponsoring clinical trial NCT07219238?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07219238's enrollment target sits among peer trials
175 396th of 2000 higher than 1,605 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia